Method for determining the in vivo interaction mode
AssigneeHoffmann-La Roche Inc.
InventorsJoerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
Life of this patent
Estimating the term…
Loading patent…
AssigneeHoffmann-La Roche Inc.
InventorsJoerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
Estimating the term…
Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
A method for determining the binding interaction with a multimeric antigen of an antibody of the human class G immunoglobulin, subclass 1 (IgG1) comprising the following steps:
A method for selecting the assay format for determining the binding interaction of an antibody of the human IgG1 subclass with a multimeric antigen comprising the following steps:
Dependencies are inferred from the claim text.